The genetic condition has been named Hypomyelination in the Brain stem and Spinal (HBSL) because those affected don't have enough myelin, the substance that coats the nerves, which leads to leg spasticity.
A global team of researchers has identified the gene behind an Australian toddler's paediatric brain disorder in a discovery that is paving the way for the diagnosis and treatment of other children with genetic diseases.
The team, led by Dr Ryan Taft from The University of Queensland's Institute for Molecular Bioscience (IMB), used genome sequencing to determine that three-year-old Massimo Damiani is suffering from a congenital disease previously unknown to medicine.
“We analysed the genome sequences of Massimo and his parents using a method called whole genome sequencing and found that a mutation in the DARS gene was likely causing his disorder,” Dr Taft said.
“In collaboration with clinicians from the Netherlands, Australia, and the US we then examined the genomes of nine other children who appeared to be suffering from the same disease and the genomes of their parents and confirmed that they all had mutations in the DARS gene.
“This gene has never previously been associated with human disease and may not have been identified as the culprit using any other method,” he said.
The team, comprised of experts from the IMB in Brisbane, VU University Medical Center in Amsterdam, Murdoch Children's Research Institute and The Royal Children's Hospital in Melbourne, and Children's National Medical Center in Washington D.C., has published their findings in the American Journal of Human Genetics.
They have named the disease HBSL because it causes Hypomyelination in the Brain stem and Spinal cord leading to Leg spasticity.
Hypomyelination occurs when people do not have enough myelin, the substance that coats nerve fibres and enables the transmission of electrical impulses in the nervous system.
“This is the future of medicine – doctors, including clinical specialists like MRI experts, and genomics researchers working together to diagnose and develop treatments for people with unknown diseases,” Dr Taft said.
Dr Taft's work was supported by next-generation sequencing technology company, Illumina.
“The ability to perform highly accurate whole-genome sequencing was critical in this discovery, with our sequencers enabling Dr Taft's team to quickly and cost-effectively scan the entire genome for mutations,” said Christian Henry, Senior Vice President and General Manager of Illumina's Genomic Solutions business.
Massimo's father, Stephen Damiani, who worked with the team, said the breakthrough came as a relief.
“Since his sudden developmental regression, soon after his first birthday, we have worked tirelessly to achieve a specific genetic diagnosis.
“Initially, all doctors could tell us was that he was suffering from a leukodystrophy, a group of diseases that cause developmental delays and often premature death of which 50% remain undiagnosed.
“Soon we ran out of tests but without knowing exactly what was causing Massimo's illness, we could not begin to devise a treatment.
“Discovering the cause of his disorder is a critical step forward to ultimately developing a therapy for him and hopefully many other children with rare genetic conditions.
The team hope their work will be used as a model for other clinicians and researchers who are faced with unknown diseases.
Indeed, Dr Taft and colleagues have already used genomics to identify the genetic mutation responsible for another leukodystrophy, H-ABC. This study was published in the same issue of the American Journal of Human Genetics.
“Our goal is to dramatically reduce the number of unresolved paediatric cases of rare genetic disease,” Dr Taft said.
It is estimated that rare diseases, 80 per cent of which are genetic in origin, collectively affect about half a million Australians.
Editor's Note: Original news release can be found here.